Applied engineering

I understand why people judge engineering by the object in front of them.

A custom ambulance looks serious. A perfusion circuit with pressure sensors looks advanced. A computer-controlled cooling system looks better than a person checking a thermometer and writing numbers on paper.

All of that can be true, and still miss the point.

In human cryopreservation, the machine is only one part of the engineering. The real job is to find where a case can lose time, control or information, then build a system that makes that specific failure less likely next time.

This is what applied engineering means at Tomorrow.bio. We do not build equipment because custom hardware looks impressive. We build it because standard equipment was usually designed for a hospital, a laboratory or a completely different procedure.

Our teams work in homes, hospitals, funeral facilities and mobile operating rooms. The system has to survive that reality.

The case defines the machine

Start with the first hours after legal death. The team needs to begin cooling, restore some circulation with mechanical chest compressions, administer medication and prepare for surgery and perfusion.

None of these tasks is extraordinary on its own. Doing them together, quickly, in an ambulance, while the situation around the patient is still changing, is the difficult part.

This is why Tomorrow.bio builds ambulances as mobile operating rooms rather than simple transport vehicles. The ice bath, pumps, tubing, surgical equipment, monitoring and cryoprotective perfusion system need to work as one setup.

The first-response procedure is extremely time-sensitive. If one component takes too long to unpack, blocks access to the patient or needs a power supply the vehicle cannot reliably provide, the design is not finished.

I think this distinction matters. A device can be technically sophisticated and operationally useless.

Tomorrow.bio's Generation 3 ambulance program is a good example of the opposite approach. The official program describes a vehicle equipped for whole-body field cryoprotection, not merely initial cooling and later transport.

That changes the purpose of the ambulance. It becomes the place where much of the procedure can happen, including the surgery, perfusion and cryoprotection that would otherwise wait for a distant facility.

The advantage is not that an ambulance is glamorous. It is that field cryoprotection can reduce the time a patient remains warm and make long-distance transport less damaging once the patient has been cooled to dry-ice temperature.

A failure should become a design change

There is a public case report that shows the engineering process better than a polished equipment page ever could.

In case CR-26-2025-22, the ambulance lost power during the procedure. The mechanical chest-compression device later stopped because of its battery level.

That is not the sentence an organization enjoys publishing.

But it is exactly the kind of sentence that makes improvement possible.

The same report records what changed afterward. Ambulances were packed with multiple batteries and chargers, the battery bank was quadrupled, and an automatic charging station was added. The report also notes planned 1,200-watt solar panels.

You can read those details in the published case report.

This is applied engineering in its least theatrical and most important form. Something failed in a real procedure. The failure was documented. The underlying system was changed.

It also explains why we publish case reports with complications rather than only showing our best outcomes.

Members have to trust that a team will be there for an event they may never see coming. A perfect marketing story is not enough for that kind of trust.

The engineering record needs to be inspectable.

Of course, one correction does not make the whole process safe. Batteries are only one failure point. Pumps can stop, sensors can drift, tubing can admit air and operators can misunderstand an alarm.

So the rule is broader: build redundancy where the consequence justifies it, keep a manual path when automation fails, and train people on the failure mode rather than only on the ideal sequence.

A cryopreservation procedure cannot be improved from memory.

The team needs timestamps. It needs patient temperatures from known probe locations, perfusion pressure, flow, cryoprotectant concentration and a record of what happened when the numbers moved outside the intended range.

In April 2025, Tomorrow.bio introduced a perfusion-circuit upgrade with fluid-level sensors in the blood reservoir and oxygenator. The stated purpose was practical: warn the operator about overflow or air entry before either becomes a larger problem.

The announcement said the upgrade was intended for ambulances, surgical rooms and flight kits. That is a useful kind of automation. It does not replace the perfusionist. It gives the perfusionist another pair of eyes during a demanding procedure.

The case record then follows the patient beyond the ambulance.

Recent Tomorrow.bio reports include temperature curves, perfusion pressure, refractive-index measurements and S-MIX calculations. The most detailed cases also include CT analysis and, with consent, tissue sampling for electron microscopy.

These measurements answer different questions. Refractive index helps track the concentration of cryoprotectant in the returning fluid.

CT can show cryoprotective distribution and areas where ice may have formed. Electron microscopy can examine neural ultrastructure at a scale a CT scanner cannot resolve.

No single number is the quality of a human cryopreservation.

Even the S-MIX metric, which compresses temperature and time into an estimate of ischemic exposure, has to sit beside the raw timeline and the rest of the evidence.

This is why our quality-check programme uses several layers of measurement. If two cases differ, we want to know where they differ, not hide the difference inside one reassuring score.

The instruments are therefore not accessories to the machine. They are what let us see whether the machine did its job.

Applied engineering is not speculative research

Tomorrow.bio also works on much harder projects: improved cryoprotective agents, intermediate-temperature storage, warming, reperfusion and concepts for eventual repair.

These projects belong on the R&D roadmap. They should not be presented as if they are all routine operating capabilities today.

Whole-body field cryoprotection, the mobile circuits used in cases, computer-controlled cooldown and cryogenic CT assessment are operating systems. New agents, whole-body intermediate-temperature storage, future warming methods and restoration remain areas of development or research at different stages.

Mixing those categories would make the company sound more advanced for five minutes and less trustworthy afterward.

Applied engineering is where the distinction becomes visible. We take what can be done now and make it faster, more measurable and more reliable. We test it in training. Then a real case shows us what training did not.

After that, we change the system again.

This loop is why Tomorrow.bio built an engineering function inside the organization instead of treating equipment as a shopping list.

The procedure is too unusual, and the feedback arrives too slowly, to expect an off-the-shelf supplier to solve every problem for us.

The most convincing engineering achievement is not the ambulance, the circuit or the cooling vessel by itself.

It is an organization that can notice a real failure, say exactly what happened and build a better version before the next call.

Further reading

First response and stabilization

Surgical procedure: perfusion and cryoprotection

Biostasis quality-check procedures

Cooldown to cryogenic temperatures